Evidence map›Paper›PMID 41368079›Full record

ArticleHemaSphere2025

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy.

Lukas Scheller, Xiang Zhou, Henry Loeffler-Wirth, Markus Kreuz, Sofie-Katrin Kadel, Sven Schimanski, Hannah Schulze, Anna Ruckdeschel, Florian Eisele, Verena Konetzki and 14 more

Abstract read
In one paragraph

Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Lukas SchellerMedizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.ORCID https://orcid.org/0000-0002-0912-1808
Xiang ZhouMedizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.ORCID https://orcid.org/0000-0001-5772-7700
Henry Loeffler-WirthInterdisziplinäres Zentrum für Bioinformatik (IZBI) Universität Leipzig Leipzig Germany.
Markus KreuzFraunhofer-Institut für Zelltherapie und Immunologie IZI Leipzig Germany.
Sofie-Katrin KadelMedizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.
Sven SchimanskiMedizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.
Hannah SchulzeMedizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.
Anna RuckdeschelMedizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.
Florian EiseleMedizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.
Verena KonetzkiLehrstuhl für Zelluläre Immuntherapie, Medizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.
Maria Jornet CulubretLehrstuhl für Zelluläre Immuntherapie, Medizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.
Maximilian MerzFraunhofer-Institut für Zelltherapie und Immunologie IZI Leipzig Germany.ORCID https://orcid.org/0000-0002-2805-5973
Julia MersiMedizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.
Johannes WaldschmidtMedizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.
Sophia DanhofMedizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.
Ulrike KöhlFraunhofer-Institut für Zelltherapie und Immunologie IZI Leipzig Germany.
K Martin KortümMedizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.ORCID https://orcid.org/0000-0002-7011-0286
Leo RascheMedizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.
Hermann EinseleMedizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.
Johannes DüllMedizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.
Max S ToppMedizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.
Michael HudecekLehrstuhl für Zelluläre Immuntherapie, Medizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.
Kristin ReicheFraunhofer-Institut für Zelltherapie und Immunologie IZI Leipzig Germany.
Miriam AlbLehrstuhl für Zelluläre Immuntherapie, Medizinische Klinik und Poliklinik II Universitätsklinikum Würzburg Würzburg Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematotoxicity and infections are the main drivers of non-relapse mortality after chimeric antigen receptor (CAR)-T therapy. Consequently, reliable predictive biomarkers are highly needed to improve risk assessment and optimize patient management. In this study, we applied the immune-related adverse outcome pathway concept to delineate key events and risk factors of CAR-T-associated hematotoxicity. To identify predictive biomarkers, we performed flow cytometry and multiplex assays before and early after CAR-T infusion on 78 patients (ide-cel

Identifiers

PMID41368079
PMCPMC12684805

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.